Predicting success of direct endoscopic necrosectomy with lumen-apposing metal stents for pancreatic walled-off necrosis - 20/08/22
Abstract |
Background and Aims |
Direct endoscopic necrosectomy (DEN) with lumen-apposing metal stents (LAMSs) is increasingly used in the management of pancreatic walled-off necrosis (WON). However, it still remains unknown which patients will fail to respond to DEN with LAMSs and require additional surgical intervention. Therefore, the aim of our study was to explore predictors of successful DEN with LAMSs for pancreatic WON.
Methods |
This is a retrospective analysis of a prospectively collected database. All consecutive patients who underwent DEN with LAMSs for pancreatic WON were included. Collected data were demographics, disease severity, morphologic features, and procedure characteristics. Potential factors affecting DEN outcome were predefined and analyzed.
Results |
One hundred one consecutive patients undergoing DEN with LAMSs for WON were identified, among whom 4 patients were excluded for technical failure (n = 1) and previous debridement without LAMSs (n = 3). In the 97 included patients, clinical success was achieved in 79 patients (81.4%). In logistic multivariable regression, 3 independent factors were negatively associated with success of DEN with LAMSs: increasing Acute Physiology and Chronic Health Evaluation II score (odds ratio [OR], .70; 95% confidence interval [CI], .55-.90; P = .005), >50% pancreatic necrosis (OR, .16; 95% CI, .03-.77; P = .022), and paracolic gutter extension (OR, .08; 95% CI, .02-.42; P = .003). A receiver-operating characteristic curve of the prediction model with these 3 factors demonstrated an area under the curve of .926.
Conclusions |
Paracolic gutter extension, increasing Acute Physiology and Chronic Health Evaluation II score, and >50% gland necrosis are negative predictors for success of DEN with LAMSs in WON. This prediction model with nomogram may be helpful in clinical decision-making and prognostication.
El texto completo de este artículo está disponible en PDF.Graphical abstract |
Abbreviations : APACHE-II, DEN, LAMS, SIRS, WON
Esquema
DISCLOSURE: The following authors disclosed financial relationships: M. Ryou: Consultant for Covidien, Olympus, Boston Scientific, Cook, GI Windows, Fujifilm, and EnteraSense. C. C. Thompson: Consultant for Olympus, Boston Scientific, Covidien/Medtronic, USGI Medical, Apollo Endosurgery, GI Windows, Aspire Bariatrics, Fractyl, Spatz, and GI Dynamics; research support from Aspire Bariatrics, Boston Scientific, Erbe, GI Dynamics, Olympus/Spiration, USGI Medical, Fuji, and Lumendi; general partner with BlueFlame Healthcare Venture Fund; founder of Enterasense Ltd, EnVision Endoscopy, and GI Windows; board member for Enterasense Ltd, EnVision Endoscopy, Fractyl, GI Windows, and USGI Medical. All other authors disclosed no financial relationships. |
|
If you would like to chat with an author of this article, you may contact Dr Thompson at mryan15@partners.org. |
Vol 96 - N° 3
P. 522 - septembre 2022 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?